These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

241 related items for PubMed ID: 739057

  • 1. Failure of factor VIII inhibitor bypassing activity (Feiba) to secure haemostasis in haemophilic patients with antibodies.
    Parry DH, Bloom AL.
    J Clin Pathol; 1978 Nov; 31(11):1102-5. PubMed ID: 739057
    [Abstract] [Full Text] [Related]

  • 2. The effect of activated prothrombin-complex concentrate (FEIBA) on joint and muscle bleeding in patients with hemophilia A and antibodies to factor VIII. A double-blind clinical trial.
    Sjamsoedin LJ, Heijnen L, Mauser-Bunschoten EP, van Geijlswijk JL, van Houwelingen H, van Asten P, Sixma JJ.
    N Engl J Med; 1981 Sep 24; 305(13):717-21. PubMed ID: 6790990
    [Abstract] [Full Text] [Related]

  • 3. Effects of low-dose 'factor VIII inhibitor bypassing activity (FEIBA)' in resistant haemophilia.
    Zwahlen H, Beck EA.
    Acta Haematol; 1980 Sep 24; 64(1):12-7. PubMed ID: 6774572
    [Abstract] [Full Text] [Related]

  • 4. Multicenter retrospective study on the utilization of FEIBA in France in patients with factor VIII and factor IX inhibitors. French FEIBA Study Group. Factor Eight Bypassing Activity.
    Negrier C, Goudemand J, Sultan Y, Bertrand M, Rothschild C, Lauroua P.
    Thromb Haemost; 1997 Jun 24; 77(6):1113-9. PubMed ID: 9241742
    [Abstract] [Full Text] [Related]

  • 5. Activated F IX concentrate (FEIBA) used in the treatment of haemophilic patients with antibody to F VIII.
    Stenbjerg S, Jørgensen J.
    Acta Med Scand; 1978 Jun 24; 203(6):471-6. PubMed ID: 665313
    [Abstract] [Full Text] [Related]

  • 6. Resistance to activated F IX concentrate (FEIBA).
    Stenbjerg S, Jorgensen J.
    Scand J Haematol; 1977 May 24; 18(5):421-6. PubMed ID: 877518
    [Abstract] [Full Text] [Related]

  • 7. [Articular and muscular hemorrhages in hemophilia A with anti-factor VIII antibodies. Treatment with selected batches of PPSB (factor IX concentrate)].
    Verroust F, Moussard C, Allain JP.
    Presse Med; 1985 May 11; 14(19):1073-6. PubMed ID: 3158962
    [Abstract] [Full Text] [Related]

  • 8. Hemophilia and von Willebrand's disease: 2. Management. Association of Hemophilia Clinic Directors of Canada.
    CMAJ; 1995 Jul 15; 153(2):147-57. PubMed ID: 7600466
    [Abstract] [Full Text] [Related]

  • 9. Comparative efficacy of nonheated and heat-treated factor IX complex concentrate in treatment of hemophiliacs with inhibitors.
    Schwartz RS, Ewing NP, Gorenc TJ, Spero JA.
    Am J Hematol; 1989 Jan 15; 30(1):22-6. PubMed ID: 2491929
    [Abstract] [Full Text] [Related]

  • 10. Inhibitor antibodies to factor VIII and factor IX: management.
    Lusher JM.
    Semin Thromb Hemost; 2000 Jan 15; 26(2):179-88. PubMed ID: 10919411
    [Abstract] [Full Text] [Related]

  • 11. Laboratory evidence of DIC under FEIBA treatment of a hemophilic patient with intracranial bleeding and high titre factor VIII inhibitor.
    Fukui H, Fujimura Y, Takahashi Y, Mikami S, Yoshioka A.
    Thromb Res; 2000 Jan 15; 22(1-2):177-84. PubMed ID: 6794176
    [No Abstract] [Full Text] [Related]

  • 12. The use of FEIBA (factor eight inhibitor bypassing activity) in cataract extraction in hemophilia A patient with inhibitor.
    Tourbaf KD, Dunlap BE, Ambrus JL, Rodman DJ, Atwal AJ.
    J Med; 1982 Jan 15; 13(5-6):399-410. PubMed ID: 6820380
    [Abstract] [Full Text] [Related]

  • 13. [Therapy of immuninhibitor hemophilia A with FEIBA plasma fraction].
    István L, Bariska I, Marton E.
    Orv Hetil; 1980 Dec 21; 121(51):3131-5. PubMed ID: 6784062
    [No Abstract] [Full Text] [Related]

  • 14. Extracorporeal immunoadsorption for the treatment of haemophilic patients with inhibitors to factor VIII or IX.
    Knöbl P, Derfler K.
    Vox Sang; 1999 Dec 21; 77 Suppl 1():57-64. PubMed ID: 10529691
    [Abstract] [Full Text] [Related]

  • 15. [Treatment of patients with hemophilia A having antibodies to factor VIII].
    Lopaciuk S, Ziemski JM.
    Acta Haematol Pol; 1979 Dec 21; 10(2):115-22. PubMed ID: 474044
    [Abstract] [Full Text] [Related]

  • 16. FEIBA: mode of action.
    Turecek PL, Váradi K, Gritsch H, Schwarz HP.
    Haemophilia; 2004 Sep 21; 10 Suppl 2():3-9. PubMed ID: 15385040
    [Abstract] [Full Text] [Related]

  • 17. [Importance of PPSB fraction in the treatment of hemophilia A with antibodies against factor VIII].
    Hrubisková K.
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1980 Sep 21; 107(4):672-82. PubMed ID: 6162735
    [Abstract] [Full Text] [Related]

  • 18. Apheresis.
    Nilsson IM, Freiburghaus C.
    Adv Exp Med Biol; 1995 Sep 21; 386():175-84. PubMed ID: 8851026
    [Abstract] [Full Text] [Related]

  • 19. Letter: Factor-VIII inhibitor bypassing activity.
    Pollock A, Lewis MJ.
    Lancet; 1976 Jul 03; 2(7975):43-4. PubMed ID: 59103
    [No Abstract] [Full Text] [Related]

  • 20. [Treatment of hemophiliacs with inhibitors].
    Fujimaki M.
    Rinsho Ketsueki; 1985 Jul 03; 26(7):1059-68. PubMed ID: 3932719
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.